Prelude Therapeutics Inc
corporate_fare Company Profile
Prelude Therapeutics Inc (NASDAQ:PRLD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for PRLD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for PRLD spans 8-K, 10-Q, SCHEDULE 13D/A, 4.
Recent high-impact activity:
- Prelude Partners with Lilly to Test KAT6A Degrader in Breast Cancer Combos
- FDA Clears Prelude Therapeutics to Begin Phase 1 Trial of PRT13722 in HR+ Breast Cancer
- FDA Clears Prelude's First-in-Class Oral KAT6A Degrader for Phase 1
- Prelude Therapeutics Narrows Q2 Loss, Extends Cash Runway into 2028
- Prelude Therapeutics Extends Cash Runway to Mid-2027 with $85.5M Offering & Reduced Burn
Financial Snapshot
Short Interest & Short Volume
11.47 days to coverFINRA reported short interest of 5,097,463 shares in PRLD as of the October 15, 2026 settlement, a 11.4% increase from the prior period — about 11.5 days to cover at its recent average daily volume. On November 6, 2026, 80.5% of PRLD volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.